GENERIC

Polyethylene Glycol 3350 + Electrolytes

Indications

For use in adults and children over 12 years of age for effective relief from constipation and treatment of chronic constipation. Also effective in resolving fecal impaction, defined as refractory constipation with fecal loading of the rectum and colon.

Pharmacology

Macrogol, also known as polyethylene glycol exerts an osmotic action in the gut, which induces a laxative effect. Macrogol increases stool volume, which triggers colon motility via neuromuscular pathways. The physiological consequence is an improved propulsive colonic transportation of the soften stools and a facilitation of the defecation. Electrolytes combined with Macrogol are exchanged across the intestinal barrier (mucosa) with serum electrolytes and excreted without net gain or loss of sodium, potassium and water. Macrogol is unchanged along the gut. It is virtually unabsorbed from the gastrointestinal tract.

Dosage and administration

For adults and children aged 12 years and above : (Powder for Suspension)

Constipation : The dose is 1 sachet daily. This may be increased to 2-3 sachets daily, if required.

Fecal Impaction : 8 sachets daily, consumed within 6 hours. A course of treatment for fecal impaction does not normally exceed 3 days.

Patients with renal insufficiency : No dosage change is necessary for treatment of either constipation or fecal impaction.

Direction of use : Each sachet should be dissolved in 125 ml water. For fecal impaction 8 sachets may be dissolved in 1 litre of water. Store the solution refrigerated and discard any solution not used within 6 hours.

For adults and children aged 12 years and above : (Oral Solution)

Constipation : 25 ml of Polyethylene Glycol 3350 and electrolytes oral solution added to 100 ml of water once daily (to make a total volume of 125 ml). This may be increased to 2-3 doses of 25 ml daily (each 25 ml dose added to 100 ml of water), if required according to individual response.

Fecal Impaction : 8 doses of 25 ml daily (each 25 ml dose added to 100 ml of water). A course of treatment for fecal impaction does not normally exceed 3 days.

Direction of use : 25 ml of oral solution added to 100 ml of water (to make a total volume of 125 ml). Any unused diluted solution should be discarded within 24 hours.

Interactions

There is a possibility that the absorption of other medicinal products could be transiently reduced during use with Movilax. There have been isolated reports of decreased efficacy with some concomitantly administered medicinal products, e.g. anti-epileptics.

Contraindications

Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, ileus, severe inflammatory conditions of the intestinal tract, such as Crohn's disease and ulcerative colitis and toxic megacolon. Hypersensitivity to the active substances.

Side effects

Generally well tolerated. However side effects like allergic reactions, electrolyte disturbances particularly hyperkalaemia and hypokalaemia, abdominal pain, diarrhea, headache, peripheral edema may appear.

Pregnancy and lactation

Clinically, no effects during pregnancy are anticipated, since systemic exposure to Macrogol (3350) is negligible. This oral solution can be used during pregnancy. No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to Macrogol (3350) is negligible. This oral solution can be used during breastfeeding.

Precautions and warnings

Patients with impaired cardiovascular function : For the treatment of fecal impaction the dose should be divided so that no more than two sachets are taken in any one hour. If patients develop any symptoms indicating shifts of fluid/electrolytes (e.g. edema, shortness of breath, increasing fatigue, dehydration, cardiac failure) Movilax should be stopped immediately and any abnormality should be treated appropriately. Prolonged use with all laxatives is undesirable and may lead to dependence.

Overdose

Severe pain or distention can be treated by nasogastric aspiration. Extensive fluid loss by diarrhea or vomiting may require correction of electrolyte disturbances.

Storage

Store below 30° C and in a place protected from light. Do not refrigerate.

Clinical information is taken from the most complete brand listing (Movilax); it applies to the active ingredient.

Brands of Polyethylene Glycol 3350 + Electrolytes

Brands of Polyethylene Glycol 3350 + Electrolytes
#BrandCompanyFormStrengthPrice
1GOLSquare Pharmaceuticals PLCOral Solution(13.125 gm+350.7 mg+178.5 mg+46.6 mg)/25 mlNot listed
2LaxogolACME Laboratories Ltd.Oral Solution(13.125 gm+350.7 mg+178.5 mg+46.6 mg)/25 mlNot listed
3MacolaxOpsonin Pharma Ltd.Oral Solution(13.125 gm+350.7 mg+178.5 mg+46.6 mg)/25 mlNot listed
4MacrosolPopular Pharmaceuticals Ltd.Oral Solution(13.125 gm+350.7 mg+178.5 mg+46.6 mg)/25 mlNot listed
5MovicolMundipharma (BD) Pvt. Ltd.Oral Solution(13.125 gm+350.7 mg+178.5 mg+46.6 mg)/25 mlNot listed
6MovicolMundipharma (BD) Pvt. Ltd.Oral Powder(13.125 gm+350.7 mg+178.5 mg+46.6 mg)/sachetNot listed
7MovifastZiska Pharmaceuticals Ltd.Oral Solution(13.125 gm+350.7 mg+178.5 mg+46.6 mg)/25 mlNot listed
8MovifastZiska Pharmaceuticals Ltd.Oral Powder(13.125 gm+350.7 mg+178.5 mg+46.6 mg)/sachetNot listed
9MovilaxIncepta Pharmaceuticals Ltd.Oral Solution(13.125 gm+350.7 mg+178.5 mg+46.6 mg)/25 mlNot listed
10MovilaxIncepta Pharmaceuticals Ltd.Oral Powder(13.125 gm+350.7 mg+178.5 mg+46.6 mg)/sachetNot listed

This page is general information and is not medical advice. It does not replace a registered doctor, and it is not a prescription or a recommendation to use any medicine or test. Prices are listed prices and may change. Always follow the advice of your doctor or pharmacist.